None of the following were significantly different: the mean age; the use of oral contraceptives; post menopausal state; underlying illness; and the mean number of episodes of vaginitis per year.
All the candida isolates recovered during study were identified as C albicans, except for three strains which were Candida non-albicans species (not further identified). One of the isolates was recovered at enrollment and two on follow-up visits, all in the intraconazole group and associated with symptoms of vaginitis.
Six patients did not complete the study; one in the itraconazole group, because of her desire to become pregnant, and five in the clotrimazole group. Two of the five patients were non-compliant with the medications and three were lost to follow up after 1-4 months. Thus, the fully evaluable patients included 21 patients in the itraconazole group and 17 patients in the clotrimazole group. Of these evaluable patients two (9.5%) receiving itraconazole had persistence of symptoms versus none in the cotrimazole group. Five other patients (23.8%) had recurrence while on suppressive therapy with itraconazole (CI Davidson and Mould5 were the first to use intermittent suppressive therapy with clotrimazole (cream and pessaries) on the 5th to 11th day of the menstrual cycle for four months. In comparison with placebo clotrimazole was highly effective in reducing symptomatic disease (1/18 versus 10/19, p < 001). However, clotrimazole did not prevent recurrent candida colonisation and recurrence were common after cessation of suppressive therapy.
In another controlled study Sobel6 randomised 74 women with recurrent vulvovaginal candidiasis to receive placebo, ketoconazole 400 mg daily for five days at the onset of menses for six months, or low dose ketoconazole 100 mg daily for six months. During the period of suppressive therapy, symptomatic recurrence of candida vaginitis occurred in 15 of 21 women (71.4%) treated with placebo, in six of 21 (28.6%) and one of 21 (4.8%) women on intermittent and daily ketoconazole respectively. After the prophylaxis was discontinued the recurrence rates were high in both treated groups.
In this study, intermittent (twice weekly) therapy with oral itraconazole or intravaginal clotrimazole appear to be effective in reducing symptomatic recurrence of candida vaginitis when compared with the results with placebo obtained in other studies.5 6 The recurrence rate with twice weekly itraconazole (23.8%) is similar to that of cyclical monthly five day courses of ketoconazole (28.6%). However, twice weekly clotrimazole intravaginally is more effective (if compliance is good) and appears to be similar in suppressive value as daily oral ketoconazole (recurrence rates 0% versus 4.8%, respectively).
The reason for the greater efficacy of clotrimazole over itraconazole may be related to a higher and more persistent concentration of active antifungal drug in the vagina. Recent pharmacokinetic studies have shown that itraconazole is variably absorbed, with wide intersubject variation in serum concentration and, thus, tissue levels may not be very predictable.11 Although the total itraconazole concentration in vaginal tissue has been found to be higher than blood levels,'2 the free (active) drug concentration in tissue fluid is much lower than the free serum concentration. 3 Although itraconazole was associated with a higher prevalence of side effects compared to clotrimazole, these were mild and well tolerated. In fact compliance was greater with itraconazole, probably because of the convenience of an oral administration. Thus, on balance (as shown by the intent to treat analysis) itraconazole and clotrimazole overall may have comparable efficacy. However, because of the relatively small sample size the power of this observation is not very high and the beta error would be significant.
The high prevalence of recurrence of candida vaginitis after discontinuation of suppressive treatment in our study is similar to the findings of Sobel,6 and Davidson and Mould.5 However, a small number of women will remain free of symptoms for six months or more after discontinuation of chronic suppressive therapy.
The choice of an agent for chronic suppressive therapy must be assessed in terms of efficacy, toxicity, compliance and cost. Both daily ketoconazole and intermittent intravaginal clotrimazole are highly effective. How-ever, there is a greater potential for systemic toxicity with ketoconazole, especially hepatotoxicity. Hepatitis has been associated with ketoconazole, and the risk of liver injury has been estimated at one in 15,000 people, especially for women over 50 years of age.6C lotrimazole may be associated with local discomfort but no systemic toxicity.
Although intravaginal administration of a medication appears to be less acceptable than oral administration, daily administration may be associated with less compliance than twice weekly administrations. Finally the cost of a six months supply of ketoconazole 100 mg daily (as recommended by Sobel, 6 ) is $170-00 versus the cost of clotrimazole 200 mg (Canesten 3), twice weekly is $228.00 (in Canada).
I am grateful to Drs P McCleary and M Simbul, Ms A Carvalho and to Mrs D Bajhan for their assistance in preparation of this manuscript. This study was supported by a grant from Janssen Pharmaceutica Inc, Canada.
